Table 2.
Quality assessment of the included studies
| Risk of bias for RCTs | ||||||||||
| Author | Year | Level of evidence | 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| Kyung-wook | 2016 | II | U | U | N | N | Y | N | N | |
| Raaij | 2008 | II | U | U | N | N | Y | N | N | |
| Lee | 2018 | II | Y | U | N | N | Y | N | N | |
| Bae | 2016 | II | Y | U | N | N | N | N | N | |
| Kim | 2017 | IV | U | U | N | N | Y | Y | N | |
| Newcastle-Ottawa assessment for cohort studies | ||||||||||
| Author | Year | Level of evidence | Selection | Comparability | Outcome | |||||
| 1(**) | 2(*) | 3(**) | 4(**) | 1(**) | 1(**) | 2(*) | 3(**) | |||
| Chiu | 1999 | III | * | * | * | * | ** | * | * | * |
| Kuwano | 2005 | III | * | * | * | * | ** | * | * | * |
| Hohmanm | 2005 | III | * | * | * | * | ** | * | * | * |
| Giffin | 2004 | III | * | * | * | * | ** | * | * | * |
| Noyes | 2005 | IV | * | * | * | * | ** | * | * | * |
| Chen | 2012 | III | * | * | * | * | ** | * | * | * |
| Ozkaya | 2008 | III | * | * | * | * | ** | * | * | * |
| Altay | 2016 | III | * | * | * | * | ** | * | * | * |
| Terauchi | 2002 | III | * | * | * | * | ** | * | * | * |
| El-Assal | 2010 | II | * | * | * | * | ** | * | * | * |
| Park | 2017 | IV | * | * | * | * | ** | * | * | * |
| Newcastle-Ottawa assessment for case-control studies | ||||||||||
| Author | Year | Level of evidence | Selection | Comparability | Outcome | |||||
| 1(**) | 2(*) | 3(**) | 4(**) | 1(**) | 1(**) | 2(*) | 3(**) | |||
| Turkmen | 2017 | III | * | * | * | * | * | * | ||
| Nakamura | 2017 | III | * | * | * | * | * | * | ||
A study was awarded a maximum of one star (*) for each item within the selection and outcome domains. A maximum of two stars (**) was givenfor comparability. More stars meant a low ROB